Jonathan Aschoff
Stock Analyst at Roth MKM
(0.43)
# 3,907
Out of 4,828 analysts
43
Total ratings
21.15%
Success rate
-35.78%
Average return
Main Sectors:
Stocks Rated by Jonathan Aschoff
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GTBP GT Biopharma | Initiates: Buy | $11 | $2.28 | +381.95% | 1 | Dec 2, 2024 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $19 → $21 | $7.87 | +166.84% | 2 | Sep 24, 2024 | |
| APVO Aptevo Therapeutics | Maintains: Buy | $555 → $296 | $0.34 | +86,958.82% | 3 | Sep 23, 2024 | |
| BRTX BioRestorative Therapies | Maintains: Buy | $15 → $18 | $1.80 | +900.00% | 4 | Aug 14, 2024 | |
| NUWE Nuwellis | Reiterates: Buy | $17 | $0.99 | +1,619.26% | 2 | Aug 13, 2024 | |
| OTRK Ontrak | Maintains: Buy | $60 → $45 | $1.64 | +2,643.90% | 2 | Aug 9, 2024 | |
| GOVX GeoVax Labs | Initiates: Buy | $20 | $0.93 | +2,056.10% | 1 | Jul 16, 2024 | |
| CYCC Cyclacel Pharmaceuticals | Maintains: Buy | $21 → $11 | $0.25 | +4,240.96% | 2 | May 3, 2024 | |
| MBRX Moleculin Biotech | Maintains: Buy | $40 | $1.05 | +3,709.52% | 2 | Apr 12, 2024 | |
| CLRB Cellectar Biosciences | Maintains: Buy | $20 → $28 | $0.25 | +11,217.70% | 4 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $36 | $6.15 | +485.37% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $75 → $360 | $4.20 | +8,471.43% | 2 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $5.69 | +427.24% | 3 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $200 | $2.63 | +7,504.56% | 1 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $14 | $2.09 | +569.86% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $2,400 → $7,200 | $3.18 | +226,450.45% | 2 | Feb 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $8 | $0.67 | +1,094.03% | 1 | Jun 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $100 | $2.14 | +4,572.90% | 1 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $400 | $0.69 | +57,462.24% | 1 | Nov 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $38 | $5.09 | +646.56% | 1 | Mar 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24,000 | $0.82 | +2,923,164.31% | 1 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $96 | $1.80 | +5,233.33% | 3 | Nov 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $6.96 | +86.78% | 1 | Dec 19, 2019 |
GT Biopharma
Dec 2, 2024
Initiates: Buy
Price Target: $11
Current: $2.28
Upside: +381.95%
Zevra Therapeutics
Sep 24, 2024
Maintains: Buy
Price Target: $19 → $21
Current: $7.87
Upside: +166.84%
Aptevo Therapeutics
Sep 23, 2024
Maintains: Buy
Price Target: $555 → $296
Current: $0.34
Upside: +86,958.82%
BioRestorative Therapies
Aug 14, 2024
Maintains: Buy
Price Target: $15 → $18
Current: $1.80
Upside: +900.00%
Nuwellis
Aug 13, 2024
Reiterates: Buy
Price Target: $17
Current: $0.99
Upside: +1,619.26%
Ontrak
Aug 9, 2024
Maintains: Buy
Price Target: $60 → $45
Current: $1.64
Upside: +2,643.90%
GeoVax Labs
Jul 16, 2024
Initiates: Buy
Price Target: $20
Current: $0.93
Upside: +2,056.10%
Cyclacel Pharmaceuticals
May 3, 2024
Maintains: Buy
Price Target: $21 → $11
Current: $0.25
Upside: +4,240.96%
Moleculin Biotech
Apr 12, 2024
Maintains: Buy
Price Target: $40
Current: $1.05
Upside: +3,709.52%
Cellectar Biosciences
Mar 28, 2024
Maintains: Buy
Price Target: $20 → $28
Current: $0.25
Upside: +11,217.70%
Mar 7, 2024
Maintains: Buy
Price Target: $25 → $36
Current: $6.15
Upside: +485.37%
Mar 5, 2024
Maintains: Buy
Price Target: $75 → $360
Current: $4.20
Upside: +8,471.43%
Feb 20, 2024
Reiterates: Buy
Price Target: $30
Current: $5.69
Upside: +427.24%
Aug 29, 2023
Reiterates: Buy
Price Target: $200
Current: $2.63
Upside: +7,504.56%
Aug 14, 2023
Reiterates: Buy
Price Target: $14
Current: $2.09
Upside: +569.86%
Feb 14, 2023
Maintains: Buy
Price Target: $2,400 → $7,200
Current: $3.18
Upside: +226,450.45%
Jun 15, 2022
Reinstates: Buy
Price Target: $8
Current: $0.67
Upside: +1,094.03%
Feb 25, 2022
Initiates: Buy
Price Target: $100
Current: $2.14
Upside: +4,572.90%
Nov 24, 2021
Initiates: Buy
Price Target: $400
Current: $0.69
Upside: +57,462.24%
Mar 11, 2021
Initiates: Buy
Price Target: $38
Current: $5.09
Upside: +646.56%
Feb 12, 2021
Initiates: Buy
Price Target: $24,000
Current: $0.82
Upside: +2,923,164.31%
Nov 17, 2020
Downgrades: Sell
Price Target: $96
Current: $1.80
Upside: +5,233.33%
Dec 19, 2019
Initiates: Buy
Price Target: $13
Current: $6.96
Upside: +86.78%